Treatment-related adverse events

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)